Join the Urinary Tract Infection group to help and get support from people like you.
Urinary Tract Infection News (Page 2)
Related terms: Acute Bacterial Cystitis, Catheter-Associated Urinary Tract Infection (UTI), Chronic Urinary Tract Infection (UTI), Cystitis, acute bacterial, Infection, Urinary Tract, UTI, Catheter-Associated Urinary Tract Infection, Chronic Urinary Tract Infection, Urinary Infection
Could Tissue-Zapping Procedure Be Non-Antibiotic Option for Recurrent UTIs?
FRIDAY, Oct. 13, 2023 – For some older women, recurring urinary tract infections — and the antibiotics typically prescribed for them — become a fact of life, but a new study offers a novel treatment ...
Treatment of Lower Urinary Tract Symptoms Tied to Reduced Risk for Death in Men
FRIDAY, Sept. 15, 2023 – For men with lower urinary tract symptoms, treatment is associated with a reduced risk for death, according to a study published in the Oct. 1 issue of The Journal of...
Early Clean Intermittent Catheterization Recommended With Neurogenic Bladder
THURSDAY, Sept. 7, 2023 – Early clean intermittent catheterization is recommended to reduce the incidence of recurrent febrile urinary tract infections (FUTIs) in children with neurogenic bladder...
Urinary Biomarkers Can Differentiate IC/BPS From Other LUTDs
WEDNESDAY, Sept. 6, 2023 – Urinary biomarkers can differentiate interstitial cystitis/bladder pain syndrome (IC/BPS) from other lower urinary-tract dysfunctions (LUTDs) in male patients, according...
FDA Approves Fetroja (cefiderocol) for the Treatment of Complicated Urinary Tract Infections
November 14, 2019 – The U.S. Food and Drug Administration today approved Fetroja (cefiderocol), an antibacterial drug for treatment of patients 18 years of age or older with complicated urinary...
FDA Approves Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections
KENILWORTH, N.J.--(BUSINESS WIRE)-- July 17, 2019 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients
DUBLIN, March 18, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA)...
Zemdri (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) – Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multidrug...
FDA Approves Vabomere (meropenem and vaborbactam) for Complicated Urinary Tract Infections
August 29, 2017 – The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis,...
FDA Medwatch Alert: Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects
ISSUE: FDA approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (i.e., taken by mouth or by injection). Includes the following currently available fluoroquinolones:...
FDA Medwatch Alert: Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections
ISSUE: FDA is advising that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated...
FDA Medwatch Alert: Zerbaxa (ceftolozane and tazobactam): Drug Safety Communication - FDA Cautions about Dose Confusion and Medication Errors
ISSUE: The U.S. Food and Drug Administration (FDA) is warning health care professionals about the risk for dosing errors with the antibacterial drug Zerbaxa (ceftolozane and tazobactam) due to...
FDA Approves Avycaz (ceftazidime and avibactam) for Complicated Abdominal and Urinary Tract Infections
February 25, 2015 – The U.S. Food and Drug Administration today approved Avycaz (ceftazidime-avibactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections...
FDA Approves Zerbaxa (ceftolozane/tazobactam) for Complicated Intra-Abdominal/Urinary Tract Infections
December 19, 2014 – The U.S. Food and Drug Administration today approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Bladder Infection, Kidney Infections, Infections
Related drug support groups
amoxicillin, doxycycline, Bactrim, Cipro, ciprofloxacin, nitrofurantoin, Macrobid, Levaquin, Augmentin, view more... trimethoprim, levofloxacin, amoxicillin / clavulanate, sulfamethoxazole / trimethoprim, Bactrim DS, cranberry, Rocephin